First biosimilar mAb in oncology granted EU approval
23 February 2017 | By Niamh Marriott, Digital Editor
The European Commission has approved Truxima (biosimilar rituximab) for all indications of reference rituximab in the European Union.
List view / Grid view
News
Vibratory sifters assure product quality and heighten productivity for global pharmaceutical manufacturers
The use of industrial sieving equipment in pharmaceutical manufacturing is critical to ensure product quality and integrity. To keep up with growing product demand, most pharmaceutical manufacturers must also improve productivity while protecting the health and safety of operators.
Apitope’s Phase II multiple sclerosis trial a success
22 February 2017 | By Niamh Marriott, Digital Editor
Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis. The Phase IIa, open-label, one arm study evaluated the effects of…
New mid-infrared laser system could detect atmospheric chemicals
21 February 2017 | By Niamh Marriott, Digital Editor
Researchers at MIT have found a new way of using mid-infrared lasers to turn regions of molecules into glowing filaments of electrically charged gas...
Scientists developed a miniature gas sensor for mobile devices
21 February 2017 | By Niamh Marriott, Digital Editor
VTT Technical Research Centre of Finland has developed a miniature gas sensor that can be connected to mobile devices.
Paresthesias nerve problems linked to World Trade Centre toxic dust
21 February 2017 | By Niamh Marriott, Digital Editor
A new study has tied the World Trade Centre (WTC) site with paresthesias, a nerve-related issue causing burning or prickling sensations...
Sustainable development indicators – can statistical indicators transform from back mirrors into drivers of change?
20 February 2017 | By Johanna Laiho-Kauranne, Director of Statistics, Luke
Johanna Laiho-Kauranne examines the 17 UN sustainable development goals that have been implemented for monitoring sustainability development...
Malaria control efforts can benefit from forecasting using satellites
20 February 2017 | By Niamh Marriott, Digital Editor
Umeå University researches have established links between patterns of malaria in Kenya and environmental factors measurable by satellite imagery...
Celltrion Healthcare & Pfizer’s biosimilar shows positive results in Crohn’s disease study
20 February 2017 | By Niamh Marriott, Digital Editor
Celltrion Healthcare presented the primary outcome from its pivotal randomised controlled trial of CT-P13 (biosimilar infliximab) in Crohn’s disease.
Custom to build £20 million Pharmaceutical Innovation Centre in Brighton
17 February 2017 | By Niamh Marriott, Digital Editor
Custom Pharma Services, the Brighton based CDMO, is pleased to announce the commencement of the building work on its £20 million Pharmaceutical Innovation Centre (PIC) in Moulsecoomb, Brighton. The Custom PIC will house the contract development, clinical and commercial manufacturing teams in a new, purpose built facility. This investment is…
FDA to review Mylan and Biocon’s biosimilar application
17 February 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has accepted Mylan and Biocon's biologics license application for MYL-1401H, a proposed biosimilar to Neulasta...
FDA approves new psoriasis drug that induced suicide in trial
17 February 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has approved Valeant’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or…
A novel and intuitive operating concept revolutionises Raman imaging
16 February 2017 | By WITec
WITec presents a new operating concept with the powerful and intuitive Suite FIVE at Pittcon 2017...
EC approves Eli Lilly’s rheumatoid arthritis drug
16 February 2017 | By Niamh Marriott, Digital Editor
The European Commission has granted marketing authorisation for Eli Lilly and Incyte’s baricitinib (Olumiant) for the treatment of moderate to severe active rheumatoid arthritis (RA), in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs).
NICE does not recommend AbbVie’s leukaemia drug
16 February 2017 | By Niamh Marriott, Digital Editor
The incremental cost-effectiveness ratios (ICERs) for venetoclax compared with best supportive care were higher than the normally range...
